

## SEQUENCE LISTING

```
Raschke, Eva
       Wolffe, Alan P
       Case, Casey C
<120> METHODS FOR BINDING AN EXOGENOUS MOLECULE TO CELLULAR CHROMATIN
<130> SABI-006/01US (S12-US1)
<140> 09/844,662
<141> 2001-04-27
<150> 60/200,590
<151> 2000-04-28
<160> 38
<170> PatentIn version 3.2
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: target site 1
<400> 1
ggggaggatc gcggaggctt
                                                                   20
<210> 2
<211> 10
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: sequence upstream of target site 1
<400> 2
ggggaggatc
                                                                   10
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: target site 2
<400> 3
gagtgtgtga actgcggggc aa
                                                                   22
<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence
```

```
<223> Description of Artificial Sequence: VEGF 1 F4
<400> 4
Thr Thr Ser Asn Leu Arg Arg
<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: VEGF 1 F5
<400> 5
Arg Ser Ser Asn Leu Gln Arg
  1
<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: VEGF 1 F6
<400> 6
Arg Ser Asp His Leu Ser Arg
<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F1
<400>-7-----
                                                Gln Ser Ser Asp Leu Gln Arq
 1
<210> 8
<211> 7
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: VEGF 3a/1 F2
<400> 8
```

```
Arg Ser Ser Asn Leu Gln Arg
<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F3
<400> 9
Arg Ser Asp Glu Leu Ser Arg
<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F4
<400> 10
Thr Thr Ser Asn Leu Arg Arg
<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F5
<400> 11
Arg Ser Ser Asn Leu Gln Arg
<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: VEGF 3a/1 F6
<400> 12
Arg Ser Asp His Leu Ser Arg
 1
                 5
<210> 13
```

```
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: GAT A 15.5 F1
<400> 13
Arg Ser Ala Asp Leu Thr Arg
<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: GAT A 15.5 F2
<400> 14
Arg Ser Asp His Leu Thr Arg
<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: GAT A 15.5 F3
<400> 15
Glu Arg Asp His Leu Arg Thr
<210> 16
<211> 7
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: GAT A 15.5 F4
<400> 16
Arg Lys Asp Ser Leu Val Arg
                  5
<210> 17
<211> 7
<212> PRT
<213> Artificial Sequence
```

```
<220>
 <223> Description of Artificial Sequence: GAT A 15.5 F5
 <400> 17
 Thr Lys Asp His Leu Ala Ser
   1
 <210> 18
 <211> 7
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: GAT A 15.5 F6
 <400> 18
 Arg Ser Asp Asn Leu Thr Arg
 <210> 19
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: VEGF forward
       primer
 <400> 19
 ctggtagcgg ggaggatcg
                                                                   19
 <210> 20
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <223> Description of Artificial Sequence: VEGF reverse
      primer
<400> 20
                                                          ----19
-geeaegacet-cegagetac-----------
<210> 21
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: VEGF probe
ctacccggct gccccaagcc tc
                                                                   22
<210> 22
```

```
<211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: pGL-VFR
       forward primer
 <400> 22
caagtgcagg tgccagaaca
                                                                    20
<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
 <223> Description of Artificial Sequence: pGL-VFR
      reverse primer
<400> 23
cgggactatg gttgctgact
                                                                    20
<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: GAPDH forward
      primer
<400> 24
ccttttgcag accacagtcc a
                                                                    21
<210> 25
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: GAPDH reverse
----primer --
<400> 25
gcagggatga tgttctggag a
                                                                    21
<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence: GAPDH probe
<400> 26
```

```
cactgccacc cagaagactg tgg
                                                                    23
<210> 27
<211> 9
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: target
      sequence 3
<400> 27
ggggaggag
                                                                    9
<210> 28
<211> 9
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: sequence complementary
      to target sequence 3
<400> 28
ctcctcccc
                                                                    9
<210> 29
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: zinc finger
      recognition helix
<400> 29
Arg Ser Asp Asn Leu Thr Arg
  1
<210> 30
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: zinc finger
      recognition helix
<400> 30
Arg Ser Asp Asn Leu Thr Arg
 1
                  5
<210> 31
<211> 7
<212> PRT
```

```
<213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: zinc finger
       recognition helix
 <400> 31
 Arg Ser Asp Ala Leu Thr Lys
 <210> 32
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: ER forward
      primer
 <400> 32
 actggctgct tcccgaatc
                                                                19
 <210> 33
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <223> Description of Artificial Sequence: ER reverse
      primer
 <400> 33
cgagtggctc agtgtgtgaa cta
                                                                23
<210> 34
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: ER probe
<400> 34
cgcacaaaca catccacaca ctctctctg
                                                               29
<210> 35
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Control
      forward primer
```

<400> 35

```
ttccgataac gaacgagact ct
                                                                   22
 <210> 36
 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Control
       reverse primer
 <400> 36
 tggctgaacg ccacttgtc
                                                                   19
 <210> 37
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Control probe
 <400> 37
 taactagtta cgcgacccc gag
                                                                   23
<210> 38
<211> 10
<212> DNA
<213> Artificial
<220>
<223> binding site for a ZFP
<220>
<221> misc_feature
<222> (1)..(2)
<223> n = any nucleotide
<220>
<221> misc_feature
<2<u>22</u>>__(3)...(<u>4</u>)
<223> (N,N) = (any nucleotide, any nucleotide) or (G,K)
<220>
<221> misc_feature
<222> (5)..(5)
<223> N = any nucleotide
<220>
<221> misc_feature
<222> (6)..(7)
<223> (N,N) = (any nucleotide, any nucleotide) or <math>(G,K)
<220>
```

```
<221> misc_feature
<222> (8)..(8)
<223> N = any nucleotide

<220>
<221> misc_feature
<222> (9)..(10)
<223> (N,N) = (any nucleotide, any nucleotide) or (G,K)

<400> 38
nnnnnnnnn
```